CN109134567B - Fermentation preparation method of nucleoside antibacterial compound - Google Patents

Fermentation preparation method of nucleoside antibacterial compound Download PDF

Info

Publication number
CN109134567B
CN109134567B CN201810811686.0A CN201810811686A CN109134567B CN 109134567 B CN109134567 B CN 109134567B CN 201810811686 A CN201810811686 A CN 201810811686A CN 109134567 B CN109134567 B CN 109134567B
Authority
CN
China
Prior art keywords
fermentation
liquid
percent
nucleoside
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201810811686.0A
Other languages
Chinese (zh)
Other versions
CN109134567A (en
Inventor
谭红
周金燕
钟娟
杨杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Institute of Biology of CAS
Original Assignee
Chengdu Institute of Biology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Institute of Biology of CAS filed Critical Chengdu Institute of Biology of CAS
Priority to CN201810811686.0A priority Critical patent/CN109134567B/en
Publication of CN109134567A publication Critical patent/CN109134567A/en
Application granted granted Critical
Publication of CN109134567B publication Critical patent/CN109134567B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/38—Nucleosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to a method for preparing a nucleoside compound with antibacterial activity, namely, a fermentation preparation method of an adriamycin (seryl-aminouracil nucleoside). Performing secondary fermentation culture in a liquid culture medium by using Streptomyces nourei and a genetically modified strain Streptomyces nourei LSP-1 (Streptomyces nourei LSP-1), and selecting a proper feeding liquid for feeding and feeding fermentation culture; the fermentation preparation process can obtain higher cell concentration and product synthesis rate, and can obtain better yield of the aliskiride. The extraction process is simple and convenient, and the recovery rate is high.

Description

Fermentation preparation method of nucleoside antibacterial compound
Field of the invention
The invention belongs to the technical field of microorganisms, and particularly relates to a fermentation preparation method of nucleoside compounds with antibacterial activity.
Background
Metabolites of microorganisms are the main source of antibiotics, nucleoside antibiotics are a generic term for a class of molecules that are usually produced by secondary metabolism of microorganisms and contain structurally modified nucleosides and nucleotides; actinomycetes are one of the most important microbial species for the production of nucleoside antibiotics. Since the discovery of streptomycin, a large number of antibiotics have been found from actinomycetes. In recent years, new antibiotics have been sought from streptomyces vulgaris, extreme environment actinomycetes, marine actinomycetes and rare actinomycetes. For example, gentamicin, erythromycin, vancomycin, rifampicin, etc. have been successfully used in clinical applications; the antibiotics applied to the control of crop diseases and insect pests include blasticidin, antimycotic 120, wuyiencin and the like; purine nucleoside antibiotics puromycin, pyrimidine nucleoside antibiotics nikkomycin, ningnanmycin, blasticidin, milomycin, gougerotin and the like developed by actinomycete metabolites have wide biological activities including antibacterial, antifungal, nematode resistant, antitumor, antiviral, immunostimulating, immunosuppression and other activities.
In the research process of producing nucleoside metabolites by microorganisms in the laboratory, a nucleoside compound is produced by fermenting an actinomycete strain, has good antibacterial bioactivity, especially has strong inhibitory activity on plant pathogenic fungi and plant viruses, and also has the function of plant immune stimulation. We named the nucleoside compound as aliskiride. Researchers complete separation and purification, physicochemical property research and structure identification of the compound through a large amount of research work for a long time; the actinomycete is subjected to strain genetic improvement to obtain an adriamycin high-yield strain, and the optimized fermentation process conditions for producing adriamycin by fermenting the high-yield strain are researched, thereby completing the invention.
Disclosure of Invention
The purpose of the invention is as follows:
one of the purposes of the invention is to provide a nucleoside compound, namely, the nucleoside compound is named as aliskiride;
the second object of the present invention is to provide a novel strain for producing aliskiride;
the third purpose of the invention is to provide a 'batch liquid culture medium flow feeding and fermenting process', which is used for producing the aliskiride by fermentation;
the fourth object of the present invention is to provide a medium for producing aliskiride.
More specifically, the invention provides a nucleoside compound (aliskiren) and a fermentation preparation method thereof, comprising the following steps:
a nucleoside compound (amissic acid) is obtained by separating and identifying from the fermentation liquor of actinomycete Streptomyces nouresei (Streptomyces noureii) collected from soil in Yibin region of Sichuan.
Culturing an actinomycete Streptomyces norsii (Streptomyces noursei) capable of producing an adriamycin and a genetically modified strain thereof in a primary liquid medium (for example, the medium A described below) as a seed solution; inoculating the cultured seed liquid into a secondary liquid culture medium (for example, a culture medium B described below) for culture; the second stage liquid medium is cultured for a suitable period of time after inoculating the first stage seed liquid, and fed-batch fermentation culture of a feed liquid (for example, feed liquid C described below) is started.
After the fermentation is finished, collecting the aliskiride from the fermentation culture solution, and carrying out separation, purification and structure identification.
In a specific embodiment of the invention, the "Streptomyces noursei" (Streptomyces noursei) or its genetically modified strain "Streptomyces noursei LSP-1" (Streptomyces noursei LSP-1) is used for secondary fermentation culture in a liquid medium, and a different medium, such as the medium A, B described below, is selected at each stage of fermentation. In the second stage fermentation, after inoculation of the first stage seed liquid, the seed liquid is cultured at a suitable temperature, for example, at 26 ℃ to 32 ℃ for 10 to 30 hours, and then fed-batch fermentation culture is carried out using a suitable feed liquid, for example, feed liquid C described below.
The feeding of the second stage liquid culture feed (e.g., feed C) can be carried out by continuous (uniform or non-uniform) feeding and/or batch feeding, with continuous feeding being preferred.
The continuous (uniform or non-uniform) feeding mode is to continuously feed a suitable feed solution (e.g., feed solution C) into the second stage fermentation tank at a certain feeding rate, e.g., 0.01-6.0L/h (uniform or non-uniform) for about 5-30 hours before stopping fermentation (discharging).
The intermittent feeding mode is a mode of adding materials once at intervals, and suitable supplement liquid (such as supplement liquid C) is fed into the second-stage fermentation tank intermittently. The batch time is preferably 1 to 12 times per 1 to 24 hours, preferably 1 time at intervals of 1 to 2 hours, the amount of each feed being 0.01 to 2.5%, preferably 0.05 to 0.5%, based on the total volume of the fermentation broth. One skilled in the art may also feed at other suitable intervals as desired.
Fermentation conditions are as follows: temperature 26-32 ℃, pH: 6-8
Fermentation time: 2-4 days
After fermentation is finished, microfiltering the fermentation liquor to remove thalli, insoluble protein and other macromolecular substances, wherein the operating pressure of the microfiltration is 0.1-0.8Mpa, the operating temperature is 1-50 ℃, the filtrate accounts for 20-90% of the volume of the feed liquid, the dialyzed water accounts for 30-90% of the volume of the feed liquid, and the filtrates are combined; and (4) concentrating the microfiltration filtrate by nanofiltration, and evaporating the obtained concentrated solution to dryness at 55 ℃ by using a vacuum rotary evaporator to obtain a brown pasty crude product. The crude product is subjected to normal phase silica gel column chromatography, and the eluent adopts chloroform: methanol: water 5: 5: 0.4, carrying out activity tracking detection on the eluent by using a tube-disc method, and collecting an active part; and then adopts C18Separating and purifying by reverse phase silica gel column chromatography, eluting with pure water as mobile phase, performing activity tracking detection and collection on the eluate, and performing high performance liquid chromatography purification preparation on the obtained active sample (preparation conditions: chromatographic column is SP-120-5-ODS-BIO4.6mmX150mm, mobile phase is methanol: water: 3: 7, flow rate: 0.8ml/min, sample introduction amount is 10ul, and detector: SPD-10A) to obtain a white powdery single compound (asilicacid) with antibacterial activity.
The chemical structure of the single compound is obtained by ultraviolet-visible light waveband scanning analysis, mass spectrometry analysis, molecular weight determination, one-dimensional and two-dimensional nuclear magnetic resonance analysis and the like of the single compound: 1-uracil-4-serylamino-1, 4-dideoxy-beta-D-glucopyranosyl uronic acid, its structure has characteristics of typical nucleoside compound, it belongs to seryl ammonia uracil nucleoside, its molecular weight is 374.1, the molecular formula is: c13H18N4O9The chemical structure is as follows:
Figure BDA0001739313600000031
aspirin (1-uracil-4-serylamino-1, 4-dideoxy-. beta. -D-glucopyranose acid,)
By adopting the process, during the second-stage fermentation, the fed-batch liquid is fed for fermentation, so that a better carbon-nitrogen ratio can be maintained, the concentration of cells in a fermentation system is improved, the utilization rate of dissolved oxygen is improved, and the yield of the aliskiren is improved.
In a preferred embodiment, the present invention further adopts a technical scheme such as a novel strain to further improve the production of the aliskiride.
In a preferred process of the invention, the invention provides, inter alia, a genetically modified strain of Streptomyces noresei "Streptomyces noresei LSP-1" (Streptomyces noversei LSP-1) for the production of aspergillonic acid; it has been preserved in China general microbiological culture Collection center (CGMCC) in 2018, 1 month and 10 days, with the preservation number of CGMCC No.15164, and the address is the institute of microbiology of China academy of sciences, No. 3, West Lu 1 Hospital, North Cheng, Chaoyang, Beijing.
The culture medium A, B and the feed liquid C adopted by the fermentation production comprise the following components in percentage by mass:
Figure BDA0001739313600000032
and (3) a culture medium B:
composition (I) General scope Preferred ranges
Starch 0.1％-5.0％ 0.3％-3.0％
Dextrin 0.1％-5.0％ 0.3％-2.0％
Sucrose/molasses 0.1％-4.0％ 0.3％-3.0％
Ammonium sulfate 0.01％-2.0％ 0.1％-2.0％
Glucose 0.1％-10.0％ 0.5％-6.0％
Peanut powder or peanut powder hydrolysate 0.1％-10.0％ 0.5％-5.0％
Soybean flour or soybean flour hydrolysate 0.1％-10.0％ 0.5％-5.0％
Corn flour 0.1％-10.0％ 0.5％-5.0％
Yeast powder 0.01％-4.0％ 0.1％-2.0％
Dipotassium hydrogen phosphate 0.01％-5.0％ 0.05％-1.0％
Magnesium sulfate 0.01％-5.0％ 0.05％-1.0％
Sodium chloride 0.01％-5.0％ 0.05％-1.0％
And (3) supplement liquid C:
composition (I) General scope Preferred ranges
Sucrose/molasses 0.1％-4.0％ 0.3％-3.0％
Glucose 0.1％-10.0％ 0.5％-6.0％
Soybean flour or soybean flour hydrolysate 0.1％-10.0％ 0.5％-5.0％
Peanut powder or peanut powder hydrolysate 0.1％-10.0％ 0.5％-5.0％
The whole process of the fermentation process of the preferred embodiment of the invention is as follows:
inoculating the activated streptomyces noursei LSP-1 strain into a culture medium A, placing the strain into a triangular flask, performing shake-flask culture at 26-32 ℃ for 20-50 hours, and then inoculating the strain into a fermentation tank added with a sterilized culture medium B by an inoculation amount of 5% -30% for fermentation production. Inoculating the strain in the second stage fermenter at 26-32 deg.C, fermenting for 10-30 hr, and feeding with feed liquid C. The feeding liquid C is fed continuously (at constant speed or non-constant speed), while the intermittent feeding is preferred.
When a continuous flow feeding mode is adopted, the feed liquid C is continuously (at a constant speed or non-constant speed) fed at the speed of 0.01-6.0L/h until about 5-30 hours before the fermentation is stopped (in a tank).
When the batch feeding mode is adopted, the batch time is preferably 1 to 12 times of feeding every 1 to 24 hours, preferably 1 time of feeding every 1 to 2 hours, and the feeding amount of each time is 0.01 to 2.5 percent of the total volume of the fermentation liquor, preferably 0.05 to 0.5 percent.
Fermentation conditions are as follows: temperature 26-32 ℃, pH: 6-8
Fermentation time: 2-4 days
After fermentation is finished, microfiltering the fermentation liquor to remove thalli, insoluble protein and other macromolecular substances, wherein the operating pressure of the microfiltration is 0.1-0.8Mpa, the operating temperature is 1-50 ℃, the filtrate accounts for 20-90% of the volume of the feed liquid, the dialyzed water accounts for 30-90% of the volume of the feed liquid, and the filtrates are combined; and (4) concentrating the microfiltration filtrate by nanofiltration, and evaporating the obtained concentrated solution to dryness at 55 ℃ by using a vacuum rotary evaporator to obtain a brown pasty crude product. The crude product is subjected to normal phase silica gel column chromatography, and the eluent adopts chloroform: methanol: water 5: 5: 0.4, carrying out activity tracking detection on the eluent by using a tube-disc method, and collecting an active part; then adopt againC18Separating and purifying by reverse phase silica gel column chromatography, eluting with pure water as mobile phase, performing activity tracking detection and collection on the eluate, and performing high performance liquid chromatography purification preparation on the obtained active sample (preparation conditions: chromatographic column is SP-120-5-ODS-BIO4.6mmX150mm, mobile phase is methanol: water: 3: 7, flow rate: 0.8ml/min, sample introduction amount is 10ul, and detector: SPD-10A) to obtain a white powdery single compound (asilicacid) with antibacterial activity.
The whole process flow of the invention is shown in figure 1.
By adopting the process, the strains produce the serine (seryl aminouracil nucleoside) with higher substrate conversion rate and product synthesis rate, and the high performance liquid chromatography is adopted to detect the content of the serine (seryl aminouracil nucleoside) (the detection condition is that a chromatographic column is SP-120-5-ODS-BIO4.6mmX150mm, the mobile phase is methanol and water is 3: 7, the flow rate is 0.8ml/min, the sample injection amount is 10ul, and the detector is SPD-10A), and the yield can reach more than 1.0 g/L.
The invention has the following advantages:
the invention provides a broad-spectrum antibacterial compound, namely, the asilicacid (1-uracil-4-serylamino-1, 4-dideoxy-beta-D-glucopyranose uronic acid, namely, seryl aminouracil nucleoside), which can be developed into a novel antibiotic.
Secondly, a genetically improved strain Streptomyces noursei LSP-1 (Streptomyces noursei LSP-1) is adopted, the substrate conversion rate and the product synthesis rate are higher, and the yield of the amifostine can reach more than 1.0 g/L.
By adopting the fermentation medium and the liquid medium flow feeding and fermenting process, the better carbon-nitrogen ratio required by the growth of the bacterial strain cells and the synthetic products can be maintained, and the better yield of the amillaridine (seryl-aminouracil nucleoside) can be obtained.
Fourthly, the extraction process flow is simple, the recovery rate is high, and the operation is convenient.
Drawings
FIG. 1 is a flow chart of the fermentation process of the present invention.
Detailed Description
Example 1
10 medium A (glucose 3.0%, peptone 1.5%, soybean cake powder 3.5%, yeast powder 0.5%, magnesium sulfate 0.05%, and sodium chloride 0.1%) is bottled in 300mL of 1000mL triangular flasks, sterilized at 120 ℃ for 30 minutes, cooled, inoculated with activated Streptomyces noresii LSP-1 spore solution, and subjected to shake-flask culture at 28 ℃ for 36 hours. Inoculating the cultured strain liquid into a 100L fermentation tank filled with 50L of a sterilization culture medium B according to the inoculation amount of 15 percent, (wherein the culture medium B comprises 3.0 percent of starch, 1.0 percent of dextrin, 3.0 percent of cane sugar, 0.5 percent of ammonium sulfate, 6.0 percent of glucose, 5.0 percent of soybean flour or soybean flour hydrolysate, 4.0 percent of peanut powder or peanut flour hydrolysate, 3.0 percent of corn flour, 1.0 percent of yeast powder, 1.0 percent of dipotassium phosphate, 0.5 percent of magnesium sulfate and 0.5 percent of sodium chloride). After fermentation at 28-30 deg.C for 14 hr under aeration and stirring, continuously feeding culture medium C (culture medium C: sucrose 1.0%, glucose 2.0%, soybean powder or soybean powder hydrolysate 3.0%, peanut powder or peanut powder hydrolysate 4.0%) at a rate of 0.7L/h until about 15 hr before fermentation is stopped (tank loading). Fermenting at pH of 6-8 for 4 days.
After fermentation, accurately measuring 42 liters of the fermentation liquor of the asplenide, carrying out microfiltration treatment on the fermentation liquor at the operating pressure of 0.2Mpa and the operating temperature of 15 ℃, carrying out microfiltration operation, measuring the volume, starting dialysis when filtrate accounts for 70% of the volume of feed liquid, stopping the machine when the added dialysis water accounts for 40% of the volume of the feed liquid, and combining the filtrates to obtain clear liquid. And (4) concentrating the microfiltration filtrate by nanofiltration, wherein the operating pressure is 0.5Mpa, the operating temperature is 15 ℃, performing nanofiltration, and evaporating the obtained concentrated solution under reduced pressure to obtain a brown pasty crude product.
The crude product is subjected to normal phase silica gel column chromatography, and the eluent adopts chloroform: methanol: water 5: 5: 0.4, further use C18Separating and purifying by reverse phase silica gel column chromatography, eluting with pure water as mobile phase; purifying by high performance liquid chromatography (preparation conditions: chromatographic column SP-120-5-ODS-BIO4.6mmX150mm, mobile phase methanol: water: 3: 7, flow rate: 0.8ml/min, sample amount of 10ul, detector: SPD-10A), concentrating and crystallizing to obtain white powdered form of aspartame (seryl-aminouracil nucleoside).
Detecting the content of the serine (seryl aminouracil nucleoside) by adopting a high performance liquid chromatography, wherein the detection conditions are as follows: the chromatographic column is SP-120-5-ODS-BIO4.6mmX150mm, mobile phase methanol: water 3: 7, flow rate: 0.8ml/min, sample size 10ul, detector: SPD-10A), through detection, the yield of the aliskiride can reach 1.2g/L fermentation liquor after 4 days of fermentation, and the product recovery rate reaches more than 80%.
Example 2
12 medium A (glucose 3.0%, peptone 2.0%, soybean cake powder 3.0%, yeast powder 0.5%, magnesium sulfate 0.5%, and sodium chloride 0.2%) are bottled in 300mL of 1000mL triangular flasks, sterilized at 120 ℃ for 30 minutes, cooled, inoculated with activated Streptomyces noresii LSP-1 spore solution, and subjected to shake-flask culture at 28 ℃ for 40 hours. Inoculating the cultured strain liquid into a 100L fermentation tank filled with 50L of a sterilization culture medium B according to the inoculation amount of 10 percent, (wherein the culture medium B comprises 2.0 percent of starch, 1.0 percent of dextrin, 2.0 percent of cane sugar/molasses, 0.5 percent of ammonium sulfate, 5.0 percent of glucose, 4.0 percent of soybean flour or soybean flour hydrolysate, 5.0 percent of peanut powder or peanut flour hydrolysate, 3.0 percent of corn flour, 1.0 percent of yeast powder, 1.5 percent of dipotassium phosphate, 1.0 percent of magnesium sulfate and 0.5 percent of sodium chloride). After fermentation at 28-30 deg.C for 20 hr under aeration and stirring, medium C (sucrose 1.5%, glucose 3.0%, soybean powder or soybean powder hydrolysate 4.0%, peanut powder or peanut powder hydrolysate 4.0%) is continuously fed at a rate of 1.0L/hr until about 20 hr before fermentation is stopped (tank loading). Fermenting at pH of 6-8 for 4 days.
After fermentation, accurately measuring 40 liters of the fermentation liquor of the asplenide, carrying out microfiltration treatment on the fermentation liquor at the operating pressure of 0.2Mpa and the operating temperature of 15 ℃, carrying out microfiltration operation, measuring the volume, starting dialysis when filtrate accounts for 70% of the volume of the feed liquid, stopping the machine when the added dialysis water accounts for 40% of the volume of the feed liquid, and combining the filtrates to obtain clear liquid. And (3) concentrating the microfiltration filtrate by nanofiltration at the operating pressure of 0.5Mpa and the operating temperature of 15 ℃, performing nanofiltration to obtain a concentrated solution, and evaporating the concentrated solution under reduced pressure to obtain a brown pasty crude extract.
The crude product is subjected to normal phase silica gel column chromatography, and the eluent adopts chloroform: methanol: water 5: 5: 0.4, further use C18Reverse phase siliconSeparating and purifying by gel column chromatography, and eluting the sample by using pure water as a mobile phase; purifying by high performance liquid chromatography (preparation conditions: chromatographic column SP-120-5-ODS-BIO4.6mmX150mm, mobile phase methanol: water: 3: 7, flow rate: 0.8ml/min, sample amount of 10ul, detector: SPD-10A), concentrating and crystallizing to obtain white powdered form of aspartame (seryl-aminouracil nucleoside).
Detecting the content of the serine (seryl aminouracil nucleoside) by adopting a high performance liquid chromatography, wherein the detection conditions are as follows: the chromatographic column is SP-120-5-ODS-BIO4.6mmX150mm, mobile phase methanol: water 3: 7, flow rate: 0.8ml/min, sample size 10ul, detector: SPD-10A), through detection, the yield of the aliskiride can reach 1.1g/L fermentation liquor after 4 days of fermentation, and the product recovery rate reaches more than 80%.
Example 3
10 medium A (glucose 3.0%, peptone 1.5%, soybean cake powder 3.0%, yeast powder 0.5%, magnesium sulfate 0.5%, and sodium chloride 0.3%) is bottled in 300mL of 1000mL triangular flasks, sterilized at 120 ℃ for 30 minutes, cooled, inoculated with activated Streptomyces noresii LSP-1 spore solution, and subjected to shake-flask culture at 28 ℃ for 36 hours. Inoculating the cultured strain liquid into a 100L fermentation tank filled with 50L of a sterilization culture medium B according to the inoculation amount of 20 percent, (wherein the culture medium B comprises 3.0 percent of starch, 1.5 percent of dextrin, 3.0 percent of cane sugar/molasses, 1.0 percent of ammonium sulfate, 6.0 percent of glucose, 5.0 percent of soybean flour or soybean flour hydrolysate, 5.0 percent of peanut powder or peanut flour hydrolysate, 3.0 percent of corn flour, 2.0 percent of yeast powder, 1.0 percent of dipotassium phosphate, 1.0 percent of magnesium sulfate and 1.0 percent of sodium chloride). After fermentation at 28-30 deg.C for 25 hr under aeration and stirring, feeding culture medium C (culture medium C: sucrose 1.5%, glucose 5.0%, soybean powder or soybean powder hydrolysate 5.0%, peanut powder or peanut powder hydrolysate 5.0%) intermittently for about 1 hr at an interval of 0.1% of the total volume of the fermentation liquid until about 10 hr before stopping fermentation. Fermenting at pH of 6-8 for 4 days.
After fermentation, measuring 41 liters of the fermentation liquor of the asplenide accurately, carrying out microfiltration treatment on the fermentation liquor at the operating pressure of 0.2Mpa and the operating temperature of 15 ℃, carrying out microfiltration operation, measuring the volume, starting dialysis when filtrate accounts for 70% of the volume of the feed liquid, stopping the machine when the added dialysis water accounts for 40% of the volume of the feed liquid, and combining the filtrates to obtain clear liquid. And (3) concentrating the microfiltration filtrate by nanofiltration at the operating pressure of 0.5Mpa and the operating temperature of 15 ℃, performing nanofiltration to obtain a concentrated solution, and evaporating the concentrated solution under reduced pressure to obtain a brown pasty crude extract.
The crude product is subjected to normal phase silica gel column chromatography, and the eluent adopts chloroform: methanol: water 5: 5: 0.4, further use C18Separating and purifying by reverse phase silica gel column chromatography, eluting with pure water as mobile phase; purifying by high performance liquid chromatography (preparation conditions: chromatographic column SP-120-5-ODS-BIO4.6mmX150mm, mobile phase methanol: water: 3: 7, flow rate: 0.8ml/min, sample amount of 10ul, detector: SPD-10A), concentrating and crystallizing to obtain white powdered form of aspartame (seryl-aminouracil nucleoside).
Detecting the content of the serine (seryl aminouracil nucleoside) by adopting a high performance liquid chromatography, wherein the detection conditions are as follows: the chromatographic column is SP-120-5-ODS-BIO4.6mmX150mm, mobile phase methanol: water 3: 7, flow rate: 0.8ml/min, sample size 10ul, detector: SPD-10A), through detection, the yield of the aliskiride can reach 1.0g/L fermentation liquor after 4 days of fermentation, and the product recovery rate reaches more than 80%.
Example 4
10 medium A (glucose 3.0%, peptone 2.0%, soybean cake powder 2.0%, yeast powder 0.5%, magnesium sulfate 0.5%, and sodium chloride 0.2%) is sterilized in 1000mL triangular flasks in 300mL of each flask at 120 ℃ for 30 minutes, cooled, inoculated with activated Streptomyces noureii spore liquid, and subjected to shake-flask culture at 28 ℃ for 36 hours. Inoculating the cultured strain liquid into a 100L fermentation tank filled with 50L of a sterilization culture medium B according to the inoculation amount of 20 percent, (wherein the culture medium B comprises 3.0 percent of starch, 1.0 percent of dextrin, 3.0 percent of cane sugar/molasses, 1.0 percent of ammonium sulfate, 4.0 percent of glucose, 3.0 percent of soybean flour or soybean flour hydrolysate, 3.0 percent of peanut powder or peanut flour hydrolysate, 2.0 percent of corn flour, 1.0 percent of yeast powder, 1.0 percent of dipotassium phosphate, 1.0 percent of magnesium sulfate and 1.0 percent of sodium chloride). After fermentation at 28-30 deg.C for 20 hr under aeration and stirring, feeding culture medium C (culture medium C: sucrose 1.0%, glucose 5.0%, soybean powder or soybean powder hydrolysate 3.0%, peanut powder or peanut powder hydrolysate 3.0%) intermittently for about 1 hr at an interval of 0.1% of the total volume of the fermentation liquid until about 10 hr before stopping fermentation. Fermenting at pH of 6-8 for 4 days.
After fermentation, accurately measuring 40 liters of the fermentation liquor of the asplenide, carrying out microfiltration treatment on the fermentation liquor at the operating pressure of 0.2Mpa and the operating temperature of 15 ℃, carrying out microfiltration operation, measuring the volume, starting dialysis when filtrate accounts for 70% of the volume of the feed liquid, stopping the machine when the added dialysis water accounts for 40% of the volume of the feed liquid, and combining the filtrates to obtain clear liquid. And (3) concentrating the microfiltration filtrate by nanofiltration at the operating pressure of 0.5Mpa and the operating temperature of 15 ℃, performing nanofiltration to obtain a concentrated solution, and evaporating the concentrated solution under reduced pressure to obtain a brown pasty crude extract.
The crude product is subjected to normal phase silica gel column chromatography, and the eluent adopts chloroform: methanol: water 5: 5: 0.4, further use C18Separating and purifying by reverse phase silica gel column chromatography, eluting with pure water as mobile phase; purifying by high performance liquid chromatography (preparation conditions: chromatographic column SP-120-5-ODS-BIO4.6mmX150mm, mobile phase methanol: water: 3: 7, flow rate: 0.8ml/min, sample amount of 10ul, detector: SPD-10A), concentrating and crystallizing to obtain white powdered form of aspartame (seryl-aminouracil nucleoside).
Detecting the content of the serine (seryl aminouracil nucleoside) by adopting a high performance liquid chromatography, wherein the detection conditions are as follows: the chromatographic column is SP-120-5-ODS-BIO4.6mmX150mm, mobile phase methanol: water 3: 7, flow rate: 0.8ml/min, sample size 10ul, detector: SPD-10A), through detection, the yield of the aliskiride can reach 0.1g/L fermentation liquor after 4 days of fermentation, and the product recovery rate reaches more than 80%.
Application example 1 use of asilicacid (seryl aminouracil nucleoside) for controlling vegetable and rice diseases: 1% seryl aminouracil nucleoside water solution is sprayed in field to prevent and treat plant bacterial diseases and viral diseases, and the disease incidence is reduced by 36%, 41%, 32% and 30% respectively compared with the control medicament, as shown in the following table.
Figure BDA0001739313600000091
Application example 2:
using 1% seryl-aminouracil nucleoside aqueous solution, and abscisic acid (ABA) with a certain concentration
When the composition is used for field spraying, the control effect and the control duration can be improved, as shown in the table below.
Figure BDA0001739313600000092

Claims (1)

1. A fermentation preparation method for preparing a nucleoside antibacterial compound 1-uracil-4-serylamino-1, 4-dideoxy-beta-D-glucopyranose uronic acid is characterized by comprising the following steps: culturing an actinomycete Streptomyces noursei genetic improvement strain Streptomyces noursei LSP-1 with the preservation number of CGMCC No.15164 in a primary liquid culture medium A to be used as seed liquid; inoculating the cultured seed liquid into a second-stage liquid culture medium B for culture, and performing fed-batch fermentation culture of a fed-batch feed liquid C; after fermentation is finished, separating and purifying the compound from a fermentation culture solution, wherein the culture medium A comprises the following components in percentage by mass:
Figure FDA0003111440480000011
the culture medium B comprises the following components in percentage by mass:
Figure FDA0003111440480000012
the feed supplement liquid C comprises the following components in percentage by mass:
Figure FDA0003111440480000013
Figure FDA0003111440480000021
。
CN201810811686.0A 2018-07-23 2018-07-23 Fermentation preparation method of nucleoside antibacterial compound Expired - Fee Related CN109134567B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810811686.0A CN109134567B (en) 2018-07-23 2018-07-23 Fermentation preparation method of nucleoside antibacterial compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810811686.0A CN109134567B (en) 2018-07-23 2018-07-23 Fermentation preparation method of nucleoside antibacterial compound

Publications (2)

Publication Number Publication Date
CN109134567A CN109134567A (en) 2019-01-04
CN109134567B true CN109134567B (en) 2021-12-24

Family

ID=64801357

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810811686.0A Expired - Fee Related CN109134567B (en) 2018-07-23 2018-07-23 Fermentation preparation method of nucleoside antibacterial compound

Country Status (1)

Country Link
CN (1) CN109134567B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1124778A (en) * 1995-08-03 1996-06-19 中国医学科学院医药生物技术研究所 Antitumor antibiotic-Yunnan-mycin
CN101967182A (en) * 2009-07-27 2011-02-09 中国科学院成都生物研究所 Antimicrobial compound and preparation method and application thereof
CN107973830A (en) * 2017-11-23 2018-05-01 中国科学院成都生物研究所 A kind of total synthesis method of new mycin difficult to understand

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1124778A (en) * 1995-08-03 1996-06-19 中国医学科学院医药生物技术研究所 Antitumor antibiotic-Yunnan-mycin
CN101967182A (en) * 2009-07-27 2011-02-09 中国科学院成都生物研究所 Antimicrobial compound and preparation method and application thereof
CN107973830A (en) * 2017-11-23 2018-05-01 中国科学院成都生物研究所 A kind of total synthesis method of new mycin difficult to understand

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Aspiculamycin, a new cytosine nucleoside antibiotic.II. Physicochemical properties and structural elucidation;Tatsuo Haneishi，等;《Journal of Antibiotics》;19740531;第27卷(第5期);第334-338页 *
Tatsuo Haneishi，等.Aspiculamycin, a new cytosine nucleoside antibiotic.II. Physicochemical properties and structural elucidation.《Journal of Antibiotics》.1974,第27卷(第5期),第334-338页. *

Also Published As

Publication number Publication date
CN109134567A (en) 2019-01-04

Similar Documents

Publication Publication Date Title
CN101967182B (en) Antimicrobial compound and preparation method and application thereof
CN101831481B (en) New method for preparing Iturin A and homolugues thereof
CN108660082B (en) Marine aspergillus derived oxaanthraquinone compound, preparation method thereof and application thereof in preparation of antibacterial agent
CN103409485A (en) Method for improving adenosine fermentation output through feeding organic nitrogen source
CN102399837B (en) Method for synthesizing acarbose through microbial fermentation
US9689017B2 (en) Method of semi-solid state fermentation for producing surfactin from a mutant strain of Bacillus subtilis subsp
CN110863021B (en) Preparation method and application of cytochalasin compound
CN113388527A (en) Physcion high-yielding strain Aspergillus chevalieri BYST1
CN101720781B (en) New phosphorus and nitrogen mycin A for preventing and controlling fungal disease of crop and preparation process thereof
CN109134567B (en) Fermentation preparation method of nucleoside antibacterial compound
CN109456899B (en) Penicillium and method for producing penicillic acid by fermenting penicillium
CN104293867A (en) Microbial synthesis method of 2'-deoxy-5'-floxuridine
CN113774002B (en) Bacillus amyloliquefaciens culture medium and application thereof
CN116218690A (en) Curvularia robusta producing cloth Lei Feide bacteria A and fermentation method thereof
CN109207536B (en) Method for increasing content of milbemycin A3 in milbemycin fermentation product
CN116103161A (en) Plant endophytic fungus for producing eupatorium and application thereof
CN101603062B (en) Method for preparing perylenequinone pigment under catalysis of Shiraia bambusicola
CN114875093A (en) Method for improving fermentation yield of PF1022A
EP0129877B1 (en) Novel antibiotic sf-2288 and its preparation method
CN104988193A (en) Production method for 10, 11-dehydrogenated curvularin and application thereof
CN109576318B (en) Method for extracting non-viable bacteria from fermentation liquor
JP2873894B2 (en) Cyclic depsipeptide and method for producing the same
CN115521877B (en) Penicillium strain and application thereof in preparation of brefeldin A
US5164507A (en) Antibiotic pyridine compound
CN113278657B (en) Fermentation method for preparing 1',4' -trans-ABA-diol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211224